Andecaliximab
Monoclonal antibody
Evidence outlook · registrational
Fibrodysplasia Ossificans Progressiva: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2029-02-04.
Development in Rheumatoid Arthritis stopped (2017-08-07) as a strategic decision by the sponsor. Development continues in another indication. Source
Development in Ulcerative Colitis stopped as a strategic decision by the sponsor. Development continues in another indication. Source
Development in Crohn's Disease stopped as a strategic decision by the sponsor. Development continues in another indication. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ANDECAL NCT06508021 · Fibrodysplasia Ossificans Progressiva Registry: NCT06508021 | 2/3 | Number of New HO Lesions as Assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)] (Week 27 and 53) 2029-02-04 | In progress: results expected 4 Feb 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Fibrodysplasia Ossificans Progressiva: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Andecaliximab: this drug | Phase 2/3 | Monoclonal antibody | Matrix metalloproteinase-9 (MMP-9) | not yet graded | No reviewed efficacy summary in this indication | |
| Garetosmab (Pasatru) | Approved | Monoclonal antibody | Activin A | Reliable signal | NCT05394116: OPTIMA (NCT05394116), primary endpoint new HO lesions by whole-body CT at week 56: 94% reduction with garetosmab 3 mg/kg vs placebo; 90% reduction with garetosmab 10 mg/kg vs placebo |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Andecaliximab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.